Leads Biolabs Reports 21.8-Month Median PFS for LBL-034
Leads Biolabs reported updated first-in-human RRMM data for LBL-034 at ESMO 2026, including a 21.8-month median progression-free survival.
Leads Biolabs reported updated first-in-human RRMM data for LBL-034 at ESMO 2026, including a 21.8-month median progression-free survival.